A phase 2 clinical trial in young adults with Down syndrome of a drug being investigated for the treatment of Alzheimer’s disease supports further investigation of its potential. Results of the four-week trial of scyllo-inositol, also known as ELND005, have been published in the Journal of Alzheimer’s Disease.
from Dementia Big http://ift.tt/2qC6Pd3 via alcoholic dementia
http://ift.tt/2rHqX1S
No comments:
Post a Comment